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Abstract 
Cardiac tumors are a rare entity, comprised of
tumors with diverse histology and natural histo-
ry.  We  report  the  clinical  characteristics,
echocardiograhic  findings,  therapy  and  out-
come of 59 patients with primary and metastat-
ic cardiac tumors. Our institutional echocardio-
gram data base from 1993 through 2005 was
reviewed  to  identify  patients  diagnosed  with
intra-cardiac tumor. A total of 59 patients with
cardiac tumors were identified and included in
the study. The patients’ characteristics, present-
ing symptoms, diagnostic tests, location, histol-
ogy of the tumor, treatment and the one year
survival  rate  of  this  population  was  collected
from  the  medical  records.  Of  the  59  cardiac
tumor  cases,  16  (27%)  were  primary  cardiac
tumors and 43 (73%) were secondary cardiac
tumors. The most common primary tumor was
sarcoma affecting 13 (81%) of the 16 cases. Of
these, 5 patients were angiosarcoma, 5 unclas-
sified  sarcoma,  one  myxoid  sarcoma  and  2
malignant fibrous histiocytoma. The mean age
at presentation was 41.1 years, and the most
common location was right atrium affecting 6
cases (37.5%). The most common symptom of
dyspnea  was  present  in  10  (62.5%)  cases.
Eleven  (25.6%)  of  the  43  secondary  cardiac
tumors were metastasis from renal cell carcino-
ma.  The  mean  age  at  presentation  was  55.4
years. Right atrium was the most frequent loca-
tion affecting 18 (42%) of the 43 patients. The
most common presenting symptom was dysp-
nea in 15 (35%) cases. For both primary and
secondary tumors, dyspnea was the most com-
mon symptom and right atrium was most fre-
quently involved. Sarcoma was the most com-
mon  primary  cardiac  tumor  while  metastasis
from renal cell carcinoma was the most com-
mon secondary tumor.
Introduction
Cardiac tumors are divided into primary and
secondary tumors. Primary cardiac tumors are
very rare, with an autopsy incidence of 0.001-
0.03%.1 Primary cardiac tumors include benign
or malignant neoplasm that may arise from any
tissue of the heart. Secondary or metastatic car-
diac tumors are 30 times more common than
the  primary  neoplasm  with  an  autopsy  inci-
dence of 1.7-14%.2The clinical manifestation of
cardiac tumor is variable and they are some-
times found on routine surveillance by echocar-
diogram. There are limited detailed reports on
large series of cardiac tumors. We report 59
cases  of  cardiac  tumors,  16  primary  cardiac
tumors and 43 secondary cardiac tumors.
Materials and Methods
We  present  a  12-year  single-institution
experience  with  cardiac  tumors  from  the
Department of Cardiology at the MD Anderson
Cancer Center. The study was approved by the
institutional  review  board.  The  echocardio-
gram  data  base  from  1993  to  2005  was
reviewed to identify patients diagnosed with
intra-cardiac tumor. For the purpose of this
study, for primary cardiac tumors both benign
and malignant primary cardiac tumors of car-
diac and pericardial origin were included in
the study. Secondary cardiac tumors with peri-
cardial metastases alone were excluded from
the study, and those with intracardiac inva-
sion with or without pericardial involvement
were included. A total of 59 patients with car-
diac  tumors  were  identified  and  all  were
included  in  the  study.  Patients’  characteris-
tics,  presenting  symptoms,  diagnostic  tests,
location, histology, treatment and 1-year sur-
vival  rates  were  collected  from  the  medical
records.  Response  to  chemotherapy  was
assessed based on revised RECIST criteria.3
Results
Of the 59 cardiac tumor cases, 16 (27%)
were  primary  cardiac  tumors  and  43  (73%)
were secondary cardiac tumors.
Primary cardiac tumors
Of the 16 primary cardiac tumors, 15 (94%)
were  malignant  and  one  (6%)  was  benign
(Table 1). Mean patient age was 41.1 years
(range 20-63 years) with 7 (44%) females and
9 (56%) males.
The most common primary tumor was sar-
coma affecting 13 (81.2%) of the 16 cases, fol-
lowed by paraganglioma in 2 (12.6%) and myx-
oma in one (6.2%). Of the 13 cases of sarco-
mas,  5  (38.5%)  were  angiosarcomas,  5
(38.5%)  were  unclassified  sarcomas,  2
(15.4%)  malignant  fibrous  histocytoma  and
one (7.7% ) was myxoid sarcoma.
The  most  common  site  was  right  atrium
(RA)  with  6  cases  (37.5%),  followed  by  left
atrium  (LA)  4  cases  (25%),  right  ventricle
(RV) 2 cases (12.5%), RA and RV one case
(6.3%),  LA  and  mitral  valve  (MV)  one  case
(7.7%),  LA/RA/MV  in  one  case  (6.3%)  and
intrapericardial one case (6.3%). The size of
the  tumor  was  known  in  14  patients  and
ranged from 1-7.7 cm.
Of the 16 cases, 14 (87.5%) were sympto-
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matic and in 2 (12.5%) cases this was an inci-
dental  finding.  The  most  common  symptom
was dyspnea; this was presented in 10 (62.5%)
cases, followed by chest pain in 4 (25%), dizzi-
ness in 2 (12.5%), cardiac tamponade in one
(6.3%)  and  palpitations  in  one  (6.3%).
Pericardial  rub  was  observed  in  2  cases
(12.5%) and systolic murmur was audible in 2
cases (12.5%). 
Data regarding chemotherapy was available
in only 11 patients. These patients were treat-
ed with various combinations of the following
chemotherapy  agents:  doxorubicin,  ifos-
famide, gemcitabine, docetaxel and epirubicin.
The most common front-line regimen was dox-
orubicin 75 mg/m2 given over 72 h as continu-
ous infusion in combination with ifosfomide
10 g/m2 per day divided over 4-5 days. The sec-
ond most common regimen was gemcitabine
675-900 mg/m2 on Day 1 and Day 8 with doc-
etaxel  60-100  mg/m2 on  Day  8  only.
Angiosarcoma  showed  the  best  response  to
therapy  compared  to  other  histological  sub-
types, but due to small sample size the differ-
ence  was  not  statistically  significant.  All  5
angiosarcoma  treated  with  adriamycin-based
therapies  showed  at  least  partial  response.
Other  histological  varieties  showed  a  less
robust response to chemotherapy.
A total of 7 (44%) patients died within one
year of diagnosis. The mean survival for malig-
nant  primary  cardiac  tumor  was  26.4±6.8
months (mean±SEM; 95% CI: 13.1-39.6). Half
the patients survived for more than 24 months
Table 1. Patients with primary cardiac tumors: characteristics, treatment and outcomes.
A/S Primary Size of Location of History Histology Surgery Chemotherapy Died within
tumor (cm) tumor Yes/No Yes/No 1 year of
diagnosis
1 43/M Angiosarcoma 5¥5.5 RA I NA No Yes Yes
2 20/F Angiosarcoma 2.4¥5 RV/RA Dyspnea Angiosarcoma Yes Yes Yes
3 55/F Angiosarcoma  4.1¥2.6 RA CP NA No Yes No
4 45/F Angiosarcoma 2..1¥4.0  RA Dyspnea,Tamponade  Angiosarcoma Yes Yes Yes
5 40/M Angiosarcoma 1¥2.5 RA Dyspnea Angiosarcoma Yes Yes No
6 56/M Sarcoma 2¥4 LA Dyspnea Unclass. sarcoma No Yes Yes
7 44/F Sarcoma 7.0¥2.0 LA/RA/MV Dyspnea Unclass. sarcoma Yes NA Yes
8 32/M Sarcoma 3.5¥3.5 LA/MV Dizziness Unclass. sarcoma Yes Yes No
9 34/M Sarcoma  NA RA Dyspnea, CP, Dizziness Unclass. sarcoma Yes Yes No
10 35/F Sarcoma  6¥7.7 Pericardium Dyspnea, CP Unclass. sarcoma No NA Yes
11 49/F Sarcoma  NA RV Dyspnea MFH Yes Yes No
12 37/F Myxoma 4.5¥2.5 RA Palpitations Myxoma Yes - No
13 26/M Paraganglioma 4¥4 LA CP Paraganglioma Yes - No
14 63/M Paraganglioma 6¥4 LA I Paraganglioma  Yes -  No
15 38/F Myxoid sarcoma 7.5¥5 RV Dyspnea Cardiac myxoid sar. Yes Yes Yes
16 26/M MFH 3.3¥2.7 LA Dyspnea, chest pain High grade Yes Yes No
sarcoma, consistent
with MFH
M, male; F, female; NA, data not available; RA, right atrium; LA, left atrium; RV, right ventricle; MV, mitral valve; I, incidental finding; TEE, ransesophageal echocardiogram; CT, computed tomography; MFH, malignant
fibrous histocytoma; A, age; S, sex; unclass., unclassified; CP, chest pain. In Patient 6, specimen for biopsy was obtained via sternotomy. In Patient 10 the diagnosis was established by cytology from pericardial fluid.
Figure 1. Survival of patients with primary cardiac tumor.Review
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(Figure 1). Of the 16 cases of primary cardiac
tumor, 12 (75%) underwent surgical resection.
Of the 12 patients who underwent surgery, 4
(33%) died within one year. Out of 4 patients
who  did  not  undergo  surgery,  3  (75%)  died
within one year.
Secondary cardiac tumors
Of the 43 secondary cardiac tumors, 23 were
males (53.5%) and 20 were females (46.5%),
with a mean age of 54.4 years (range 24-82
years) (Tables 2 and 3). Eleven (25.6%) of the
43 secondary cardiac tumors were metastases
from renal cell carcinoma, 6 (14%) from sarco-
mas  (pleura,  retroperitoneal,  pelvis,
endometrium, mediastinum and inferior vena
cava), 6 (14%) from melanoma, 6 (14%) from
lung  cancer,  3  (7%)  from  breast  cancer,  2
(4.7%) from carcinoid tumor. 
The RA was the most frequent site affecting
18 (41.9%) of the patients, followed by LA in 13
(30.2%), left ventricle (LV) in 7 (16.3%), RV in
2 (4.7%), RA/RV in 2 (4.7%) and LA/RA in one
(2.3%). 
The size of the tumor was available in 35
patients and it ranged from less than 1 cm to
11 cm. 
Of the 43 cases, 24 (56%) had symptoms and
in 19 (44%) cases this was an incidental find-
ing. The most common symptom was dyspnea,
which was present in 15 (35%) cases, followed
by  palpitations/atrial  fibrillation/atrial  flutter
in  5  (11.6%),  chest  pain  in  3  (7%),  ankle
edema in 4 (9%), syncope/near syncope in 2
(4.7%), dizziness in one (2%) and hypotension
in one (2%). Systolic murmur was observed in
11 cases (25.6%). 
A total of 23 (53.4%) patients died within
one year of diagnosis of secondary tumor. Of
the 43 patients with secondary cardiac tumors,
23  (53.5%)  underwent  surgical  resection,  of
which 13 (56.5%) were alive and 10 (43.5%)
were dead at one year of diagnosis. Of the 20
patients who did not undergo surgery, 7 (35%)




The  majority  (>80%)  of  primary  cardiac
tumors are benign; myxoma is the most com-
mon.4,5 The remaining 20% are malignant pri-
mary cardiac tumors, of which cardiac sarco-
mas are the most common.4,5 However, in our
series  the  most  common  primary  cardiac
tumor  was  malignant  cardiac  sarcoma.  Our
institution  is  a  tertiary  referral  center  for
malignant  disorders  and  this  probably
explains  this  population  bias  of  predomi-
nance  of  malignant  over  benign  cardiac
tumors. Review of the literature reveals that
primary cardiac sarcoma constitutes approxi-
mately 1% of all soft tissue sarcomas, with a
median age of presentation of 39-44 years.6
Cardiac tumors cause disease in three sep-
arate mechanisms: embolization, obstruction
and  arrhythmias.  Embolization  occurs  fre-
quently,  fragments  of  the  tumor  itself  can
migrate, this may mimic endocarditis or vas-
culitis, and larger particles can cause cere-
brovascular events. Atrial tumors, when large
enough,  may  result  in  obstruction  which
impedes valvular flow, resulting in obstructive
symptoms  like  syncope  or  congestive  heart
failure  (CHF).  Similarly,  ventricular  tumors
may  block  outflow  tracts  resulting  in  chest
pain,  shortness  of  breath  or  syncopal
episodes, as well as CHF. Finally, tumors can
cause  intra-myocardial  and  intra-cavitary
infiltration, and affect the conduction system
resulting in heart block, arrhythmias and ven-
tricular  tachycardia,  which  may  present  as
sudden death.7 The most common presenting
symptoms  are  dyspnea,  followed  by  chest
pain,  cough,  syncope,  hemoptysis,  sudden
death, fever, embolic events, cardiac arrhyth-
mias,  hepatic  vein  and  superior  vena  caval
obstruction.8,9 Physical findings such as sys-
tolic  murmur,  diastolic  murmur,  elevated
jugular venous pressure and tumor plop may
be present.10 Cardiomegaly is a common radi-
ological  finding  of  cardiac  sarcomas.9
Electrocardiogram (ECG) changes are usually
non-specific; however, heart block, ventricu-
lar hypertrophy, bundle branch blocks, atrial
flutters and atrial tachycardia may be present
in  some  cases.9 In  our  series,  38  patients
(64.4%)  were  symptomatic  and,  similar  to
other reports, the most common presenting
symptom  was  dyspnea  (66%)  followed  by
chest pain (21%). In 21 of 59 (35.6%) cases
this was an incidental finding (Table 4).
Nearly half of the primary tumors in the
right atrium are malignant and are predomi-
nantly found in males. The majority of the left
atrial primary tumors are benign.5 Previously,
primary cardiac tumors were identified at an
advanced stage, but in the past two decades
have been identified at an earlier stage due to
better  modalities  of  cardiac  imaging.
Echocardiogram is used in the initial diagno-
sis of primary cardiac tumors with transtho-
racic echocardiogram being the initial modal-
ity.  However,  there  are  several  well  known
limitations,  such  as  operator  experience,
restricted field of view due to bone and lung
interference,  and  unfavorable  body  habitus
such  as  chronic  obstructive  pulmonary  dis-
ease or narrow rib spaces. Transesophageal
echocardiogram and especially cross section-
al  imaging  methods  such  as  computerized
tomography  (CT  scan)  and  magnetic  reso-
nance imaging (MRI) have roles in further
assessment of cardiac neoplasm, especially in
evaluation  of  myocardial  invasion,  involve-
ment  of  mediastinal  structures  and  tissue
characterization and vascularity.11-14 CT scan
is useful in predicting extra cardiac extension
of tumor, while MRI scan is better in identify-
ing the amount of myocardial and great vessel
involvement.5 Complete  resection  of  the
tumor is possible in most of the benign pri-
mary tumors compared to malignant tumors,
with a perioperative death of 1.4%.5
Cardiac  sarcomas  are  the  commonest  of
the  malignant  primary  cardiac  tumors.  The
age  of  presentation  for  cardiac  sarcomas
ranges from one to 76 years, with a mean age
around 40 years.9 Angiosarcomas and unclas-
sified sarcomas account for 76% of all cardiac
sarcomas,  of  which  angiosarcomas  are  the
most common followed by unclassified sarco-
mas.15 In our study, 77% of the cardiac sarco-
mas  were  angiosarcomas  and  unclassified
sarcomas.  Rhabdomyosarcoma  is  the  most
common form of cardiac sarcoma in children.
Leiomyosarcoma, synovial sarcoma, osteosar-
coma, fibrosarcoma, myxoidsarcoma, liposar-
coma, mesenchymal sarcoma, neurofibrosar-
coma,  malignant  fibrous  histocytoma  are
other  cardiac  sarcomas  observed.8,15
Angiosarcomas  are  predominantly  found  on
the  right  side  while  osteosarcomas  and
unclassified  sarcomas  are  predominantly
found  on  the  left  side  of  the  heart.9,15
Pericardial  angiosarcomas  are  rare.  All  5
(100%)  angiosarcomas  in  our  series  were
found in the RA. Of the 5 unclassified sarco-
mas in our series, 3 (60%) were in the LA,
one (20%) was in the RA and one (20%) was
in the pericardium. About 29% of cardiac sar-
comas have metastatic disease at the time of
presentation.8 The  most  common  site  of
metastasis is lung.8,9 In our series, 3 (23%) of
the 13 cardiac sarcoma patients had metasta-
sis at the time of presentation; two of them
had metastases in the lung and one in the
liver. 
For treatment purposes, cardiac sarcomas
are divided into three groups: right heart sar-
comas,  left  heart  sarcomas  and  pulmonary
artery  sarcomas.16 The  treatment  for  right
heart and left heart sarcomas is surgery and
chemotherapy.  Radiotherapy  is  avoided  in
these  patients  as  it  may  cause  myocardial
injury. Treatment of pulmonary artery sarco-
mas  includes  surgery,  chemotherapy  and
radiotherapy.  Radiotherapy  can  be  used  in
these  sarcomas  as  myocardium  is  shielded
from the radiation field.16 The most common
chemotherapeutic regimen used for cardiac
sarcomas is combined doxorubicin and ifos-
famide. More than half of the cardiac sarcoma
patients who received chemotherapy in our
series received doxorubicin and ifosfamide. A
combination  of  docetaxel  and  gemcitabine
also showed good response in various sarco-Review
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Table 2. Patients with secondary cardiac tumors: characteristics, treatment and outcome.
A/S Primary Size of Location of History Histology  Surgery Died within
tumor tumor(cm) tumor Yes/No 1 year of
diagnosis 
1 57/M Renal cell carcinoma NA RA I NA  Yes No
2 40/M Renal cell carcinoma NA LA I RCC Yes Yes
3 69/M Renal cell carcinoma NA RA Ankle edema RCC Yes No
4 72/M Renal cell carcinoma 4¥5  RA I RCC Yes No
5 43/F Renal cell carcinoma NA RA Dyspnea Collecting duct ca. Yes Yes
6 33/M Renal cell carcinoma 4¥3 LA I NA No Yes
7 78/F Renal cell carcinoma 1.5¥1.4 RA I Sarcomatoid ca. Yes Yes
8 52/F Renal cell carcinoma 3.5¥2.2 LV I NA No Yes
9 65/M Renal cell carcinoma 2.2¥1.5 LA Dyspnea NA No No
10 56/F Renal cell carcinoma NA RA/RV Dyspnea, edema RCC Yes Yes
11 60/M Renal cell carcinoma NA RA Dyspnea, edema RCC Yes No
12 24/F Pleural sarcoma 1.6¥1.4 LV Dyspnea NA No Yes
13 50/M Pleomorphic liposar. 6.3¥2.7  LV Dyspnea Pleomorphic sar. Yes Yes
14 15/M Undiff. sarcoma pelvis 0.7¥0.8 RA/RV I Sarcoma Yes No
15 31/F Endometrial sarcoma NA RA Dyspnea Sarcoma Yes No
16 54/F Leiomyosarcoma (med.) 3.5¥4.1 RA I Leiomyosarcoma Yes No
17 56/F Leiomyosarcoma (IVC) 3.1¥2.4 RA I Leiomyosarcoma Yes Yes
18 56/M Malignant melanoma 1.9¥1.9 RA Dyspnea NA No Yes
19 56/M Malignant melanoma 2.5  LV Hypotension NA No Yes
20 39/F Malignant melanoma 5.5¥3  LA Dyspnea, palpitation, syn. Metastatic melanoma Yes No
21 32/M Malignant melanoma 7¥11 LA Chest pain Metastatic melanoma Yes Yes
22 67/M Malignant melanoma 4.0¥2.0 RA I NA Yes No
23 40/M Malignant melanoma 3.3¥3.8 RA Chest pain Metastatic melanoma Yes Yes
24 59/M Sarcomatoid lung can. 1.3¥0.6 RA Dyspnea NA Yes No
25 43/M Unclass. large cell ca. lung NA RA Dyspnea NA No Yes
26 75/F Non small cell ca. lung 2.1¥2.5 LA Palpitations Poorly diff. adenoca. Yes Yes
27 51/F SCC lung 3¥2 LA Dyspnea SCC Yes Yes
28 71/M SCC lung 3.3¥1.6 LA Atrial flutter NA No Yes
29 46/M Adenocar. lung 6.0-7.0 LA I Adenocarcinoma Yes No
30 42/F Inf. ductal ca. breast 2.5¥2.5 LA Dyspnea NA No Yes
31 44/F Adenoca. breast 4.6¥2.0 RV I NA No Yes
32 78/F Inf. ductal ca. breast 1.5¥1.5  RA Dyspnea, edema, CHF NA No No
33 56/F Carcinoid tumor  3.7¥3.9 RA/LA I NA No No
34 71/M Carcinoid syndrome 3.0¥3.0 RV I NA No No
35 49/F MFH (colon) 3.3¥2.4 LA I NA No No
36 43/F Transitional and SCC (bl.) 2.6¥1.0  LV I NA No Yes
37 82/M Rectal adenocar. 2.5¥4  RA Dizziness, syncope NA No Yes
38 80/M SCC (tongue) 3.1¥1.0 RA Irregular heart rhythm NA No No
39 62/F Large B-cell lymphoma 1.0¥1.0  LV I NA No Yes
40 57/M Multiple myeloma 3.9¥4.8  LA I NA No Yes
41 43/F Leiomyoma (uterus) 4¥3.8 RA Dyspnea, palpitation Smooth muscle tum. Yes No
42 42/F Smooth cell tumor (thigh) 1.8¥3.5 LV Chest pain NA No No
43 63/M Carcinoid neuroendocrine tumor 3.5¥4.3 LA I NA Yes No
A, age; S,sex; M, male; F, female; NA, not available; RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; MV, mitral valve; I, incidental; TEE, transesophageal echocardiogram; CT, computed tomography;
MRI, magnetic resonance imaging; IVC, inferior venacava; CHF, congestive heart failure; CA, carcinoma; SCC, squamous cell carcinoma; AML, acute myeloid leukemia; ca., carcinoma; sar., sarcoma; syn., syncope; diff.,
differentiated; Inf., infiltrative; unclass., unclassified; undiff., undifferentiated; RCC, renal cell carcinoma; adenocar., adenocarcinoma; tum., tumor; MFH, malignant fibrous histocytoma; med., mediastinum; bl., blad-
der.Review
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mas  and  can  be  used  as  alternative
chemotherapeutic agents.17 Other treatment
regimens include ifosfamide-epirubicin (dox-
orubicin) and cyclophosphamide, vincristine,
doxorubicin and dacarbazine (CyVADIC).6
Unlike  other  sarcomas,  cardiac  sarcomas
have a very poor prognosis with a median sur-
vival rate of 6-25 months after diagnosis.9,15
Presence of tumor necrosis and metastases is
associated with a poor prognosis.8,9 A recent
study  showed  that  14.8%  of  the  resected
tumors were low grade and all the patients
were alive at follow up.18 This underlies the
importance of tumor grade in survival of post-
operative  patients.  Sarcomas  other  than
angiosarcomas, sarcomas on the left side of
the heart and completely resected sarcomas
have  a  better  prognosis.8,9 Angiosarcomas
grow faster, infiltrate widely, and metastasize
early; they therefore have a poor prognosis.
Secondary cardiac tumors
The autopsy incidence of secondary cardiac
tumors  ranges  from  1.7  to  14%  (average
7.1%)  in  cancer  patients  and  0.7  to  3.5%
(average 2.3%) in the general population.2 In
comparison to older series, there is a signifi-
cant  increase  in  the  incidence  of  cardiac
metastases  (CM)  in  cancer  patients  after
1970.2 This is likely due to improvement in
imaging modalities.
Sarcomas that affect the myocardium are
mostly  high  grade  and  progress  swiftly.
Myocardial  infiltration,  outflow  obstruction
and distant metastasis result in death within
a few weeks to two years of onset of symp-
toms,  median  survival  ranging  from  6-12
months.  Different  series  documented  the
metastatic rate to be 26-43% at presentation
and 75% at the time of death.8,9,19-27 CM can
occur  either  by  direct  extension,  via blood
stream, lymphatics or by intracavitary diffu-
sion  through  inferior  vena  cava  (IVC).
Pericardial  metastasis  (69%)  is  the  most
common  type  of  CM,  followed  by  epicardial
(34%),  myocardial  (32%)  and  endocardial
metastases (5%).28 Pericardium is most often
involved due to direct invasion by the thoracic
cancers. Myocardium or epicardium is most
commonly involved through lymphatic spread
and  endocardial  metastases  through
hematogenous spread. Abdominal and pelvic
tumors may reach the RA through IVC. The
most common tumor exhibiting this tendency
is renal cell carcinoma. Three patients with
renal cell carcinoma in our series had right
atrial metastases via the IVC. 
Table 3. Demographics of secondary car-
diac tumors (n=43).
Primary tumor N (%)
Renal cell carcinoma 11 (25.6)
Sarcoma 6 (14)
Malignant melanoma 6 (14)
Lung cancer  6 (14)
Breast cancer 3 (7)
Carcinoid tumor  2 (4.7)
Lymphoma 1 (2.3)
Leukemia 1 (2.3)
Multiple myeloma 1 (2.3)
Colon/rectal cancer 1 (2.3)
Leiomyoma 1 (2.3)
Squamous cell carcinoma of tongue 1 (2.3)
Neuroendocrine tumor 1 (2.3)
Smooth muscle tumor 1 (2.3)
Bladder cancer 1 (2.3)
N, numbers.
Table 4. Clinical symptoms of symptomatic cardiac tumors (n=38)*.
Clinical symptoms P+S (38) P (14) S (24)
N (%) N (%) N (%)
Dyspnea 25 (66) 10 (71) 15 (63)
Chest pain 8 (21) 5 (36) 3 (13)
Palpitation/atrial flutter/atrial fibrillation 6 (16) 1 (7) 5 (21)
Ankle edema 4 (10) 0 4 (17)
Dizziness 3 (8) 2 (14) 1 (4)
Syncope 2 (5) 0 2 (8)
Tamponade 1 (3) 1 (7) 0
Hypotension 1 (3) 0 1 (4)
*Of the 59 cases in the study, 38 were symptomatic; 21 were incidental findings. P, primary cardiac tumors; S, secondary cardiac tumors; N,
numbers. Some patients had more than one of the above sympthoms.
Table 5. Reported primary origin of secondary cardiac tumors (including pericardial invasion).
Author Year  CM cases Most common N (%) 2nd most N (%) Chamber/side
primary  common primary involved
1 Bussani et al.28 2007 662 Lung cancer  263 (38%) Leukemia/ malignant lymphoma  67 (10%) NA
2. Hanfling29 1960 122 Leukemia 34 (28%) Lymphoma 27 (22%) NA
3 Cates et al.30 1986 47 Lung cancer 25 (53%) Leukemia/ lymphoma 5 (11%) NA
4. Butany et al.31 2005 264 Lung cancer  - Leukemia/ multiple myeloma - NA
5 Rafajlovski et al.32 2005 79 Lung cancer  18 (23%) Leukemia/ malignant lymphoma 16 (20%) LV
6 Abraham et al.33 1990 95 Lung cancer  - Lymphoma - NA
7 Karwinski et al.34 1989 130 Lung cancer 60 (46%) Malignant melanoma 13 (10%) NA
8 Goudie35 1954 126 Lung cancer  85 (67%) Lymphadenoma/reticulosar. 10 (8%) Lt side (37%) 
Rt.side (28%) 
Both (35%)
9. Lockwood et al.36 1980 179 Lung cancer  108 (60%) Kidney 14 (8%) NA
10 Silvestri et al.37 1997 162 Melanoma  (48%) Lung cancer (29%) NA
11. Abioye et al.38 1975 64 Burkitt's lymphoma  30 (31%) Hodgkin's disease 4 (6%) RA(31.25%)
12 De Loach et al.39 1953 137 Lung cancer 22 (16%) Reticulum cell sarcoma 18 (13%) Rt side (86%), 
Right ventricle (46%)
13 Mac Gee et al.40 1991 57 Lung cancer  20 (40%) Breast cancer 11 (22%) LV (77%)
14 Manojlovic41 1990 39 Lung cancer 17 (44%) Tongue and sublingual region 9 (23%) Lt. side
CM, cardiac metastases; NA, not available; sar., sarcoma, Lt, Left; Rt, right;.LV, left ventricle, RA, right atrium.Review
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Review of previous report shows that lung
cancer is the most common cause of cardiac
metastasis  followed  by  hematologic  malig-
nancy. Only a couple of reports show a differ-
ent trend (Table 5).28-41 In our study, about
25.6%  of  the  intra-cardiac  metastases  were
from renal cancer followed by 14% from sarco-
mas, 14% each from malignant melanoma and
lung  cancer.  Breast  cancer  and  carcinoid
tumor were the primary source for 7% and
4.7% of the secondary cardiac tumors, respec-
tively. In the previous reports, the most com-
mon side/chamber of the heart involved with
CM varied from study to study (Table 5).28-41
In  our  study,  both  sides  of  the  heart  were
equally  affected  and  right  atrium  was  the
most  commonly  involved  chamber  of  the
heart. 
The symptoms of CM are extremely vari-
able, depending on the location of the tumor.
Dyspnea,  palpitations,  syncope,  chest  pain
and  peripheral  edema  are  common  clinical
presentations  of  CM.28-29 Congestive  heart
failure,  cardiac  arrhythmias,  heart  blocks,
acute myocardial infarction, myocardial rup-
ture  and  systemic  embolization  are  other
manifestations of CM.29 A new heart murmur
of stenosis or any new ECG finding without
any  symptoms  in  a  cancer  patient  should
raise the suspicion of CM.29-30 The ECG find-
ings commonly found in CM are ST-T wave
changes (mimicking myocardial ischemia or
injury), new atrial fibrillation or flutter and
low  voltage  ECG.30 The  ECG  findings  of
myocardial  injury  have  high  specificity  for
CM.30
Treatment of metastatic cardiac tumors is
usually  palliative.  Different  series  have
shown  that  the  median  survival  is  17-24
months for patients who can undergo com-
plete resection and 6-10 months for patients
unable  to  undergo  complete  resection.8,12
Surgery  with  post-operative  chemotherapy
and/or  radiotherapy  to  prevent  local  recur-
rence  is  indicated  in  patients  with  better
prognosis and when they have only CM with-
out disseminated disease.2 Orthotopic heart
transplantation  is  an  option  in  selected
patients,  with  improved  survival.  42,43 In
patients  with  disseminated  disease,  limited
life expectancy and poor performance status,
radiotherapy  is  the  treatment  of  choice.
Chemotherapy  is  recommended  for  tumors
which are chemo-sensitive. In these patients,
end of life care should be discussed and all
efforts  should  be  made  to  improve  patient
quality of life.
In conclusion, in our tertiary center, sarco-
ma  was  the  most  common  primary  cardiac
tumor while metastasis from renal cell carci-
noma  was  the  most  common  secondary
tumor. Dyspnea was the most common symp-
tom  and  RA  was  most  frequently  involved.
Overall prognosis for primary cardiac sarco-
ma is poor, with 54% patients dying within
one year of diagnosis.
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